WO1999027123A3 - Modified sv40 viral vectors - Google Patents

Modified sv40 viral vectors Download PDF

Info

Publication number
WO1999027123A3
WO1999027123A3 PCT/US1998/025225 US9825225W WO9927123A3 WO 1999027123 A3 WO1999027123 A3 WO 1999027123A3 US 9825225 W US9825225 W US 9825225W WO 9927123 A3 WO9927123 A3 WO 9927123A3
Authority
WO
WIPO (PCT)
Prior art keywords
vectors
modified
viral vectors
provides
genes
Prior art date
Application number
PCT/US1998/025225
Other languages
French (fr)
Other versions
WO1999027123A9 (en
WO1999027123A2 (en
Inventor
Bingliang Fang
Steven L Highlander
Kevin S Casement
Jack A Roth
Original Assignee
Univ Texas
Bingliang Fang
Steven L Highlander
Kevin S Casement
Jack A Roth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas, Bingliang Fang, Steven L Highlander, Kevin S Casement, Jack A Roth filed Critical Univ Texas
Priority to AU15369/99A priority Critical patent/AU1536999A/en
Publication of WO1999027123A2 publication Critical patent/WO1999027123A2/en
Publication of WO1999027123A3 publication Critical patent/WO1999027123A3/en
Publication of WO1999027123A9 publication Critical patent/WO1999027123A9/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
    • C12N2710/22041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/22043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention provides SV40-based viral vectors for use in the delivery of genes to target cells. The unique combination of multiple viral systems provides for vectors with increased carrying capacity and extended host range when compared to normal SV40 vectors. Uses for the vectors include the expression of proteins in vitro and in vivo.
PCT/US1998/025225 1997-11-26 1998-11-25 Modified sv40 viral vectors WO1999027123A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU15369/99A AU1536999A (en) 1997-11-26 1998-11-25 Modified sv40 viral vectors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97853997A 1997-11-26 1997-11-26
US08/978,539 1997-11-26

Publications (3)

Publication Number Publication Date
WO1999027123A2 WO1999027123A2 (en) 1999-06-03
WO1999027123A3 true WO1999027123A3 (en) 1999-08-12
WO1999027123A9 WO1999027123A9 (en) 1999-09-16

Family

ID=25526193

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/025225 WO1999027123A2 (en) 1997-11-26 1998-11-25 Modified sv40 viral vectors

Country Status (2)

Country Link
AU (1) AU1536999A (en)
WO (1) WO1999027123A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6656732B1 (en) 2001-05-18 2003-12-02 Isis Pharmaceuticals, Inc. Antisense inhibition of src-c expression
WO2007064971A2 (en) * 2005-12-01 2007-06-07 The Government Of The Usa, As Represented By The Secretary, Dept. Of Health & Human Services Infectious papovavirus particle comprising a cytocidal gene and methods of use thereof
GB2439543A (en) * 2006-06-27 2008-01-02 Viruvation B V Polyoma viral vector production cell lines and nucleic acids expressing dsRNA viral sequences
EP2243836A1 (en) 2009-04-22 2010-10-27 Amarna Therapeutics B.V. Method for the production of recombinant polymavirus vector particles
EP3105311A1 (en) 2014-02-10 2016-12-21 Univercells NV System, apparatus and method for biomolecules production

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0300422A2 (en) * 1987-07-21 1989-01-25 The Du Pont Merck Pharmaceutical Company An improved method for preparing stable and viable recombinant animal cell viral vectors
WO1996020598A1 (en) * 1994-12-30 1996-07-11 Thomas Jefferson University Gene transduction system
WO1997000326A1 (en) * 1995-06-15 1997-01-03 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0300422A2 (en) * 1987-07-21 1989-01-25 The Du Pont Merck Pharmaceutical Company An improved method for preparing stable and viable recombinant animal cell viral vectors
WO1996020598A1 (en) * 1994-12-30 1996-07-11 Thomas Jefferson University Gene transduction system
WO1997000326A1 (en) * 1995-06-15 1997-01-03 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FANG B. ET AL.: "A packaging system for SV40 vetors without viral coding sequences", ANALYTICAL BIOCHEMISTRY, vol. 254, no. 1, 1 December 1997 (1997-12-01), pages 139 - 143, XP002102712 *

Also Published As

Publication number Publication date
WO1999027123A9 (en) 1999-09-16
AU1536999A (en) 1999-06-15
WO1999027123A2 (en) 1999-06-03

Similar Documents

Publication Publication Date Title
CA2323086A1 (en) Regulation of endogenous gene expression in cells using zinc finger proteins
AU6133394A (en) Targeting and delivery of genes and antiviral agents into cells by the adenovirus penton
CA2285667A1 (en) Viral vectors having chimeric envelope proteins containing the igg-binding domain of protein a
AU7264694A (en) Defective adenovirus vectors and use thereof in gene therapy
EP1180932A4 (en) Infectivity-enhanced conditionally-replicative adenovirus and uses thereof
EP0844888A4 (en) Tissue specific viral vectors
WO2000054813A3 (en) Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
EP1923467A3 (en) Adenovirus vectors for gene therapy
IL132951A0 (en) Compounds preparation and use for transferring nucleic acids into cells
AU2853395A (en) Recombinant vectors derived from adenovirus for use in gene therapy
HK1038382A1 (en) Delivery of proteins into eukaryotic cells with recombinant yersinia
ZA971158B (en) Nucleic acid constructs for the cell cycle-regulated expression of genes, cells containing such constructs and their use for preparing drugs.
AU5846598A (en) Promoter of the CDC25B gene, its preparation and use
AU7748200A (en) Hypoxia-related human genes, proteins, and uses thereof
WO1999046371A3 (en) Induction of apoptotic or cytotoxic gene expression by adenoviral mediated gene codelivery
WO1999027123A3 (en) Modified sv40 viral vectors
AU5318496A (en) Adenovirus vectors for gene therapy
WO2003018836A3 (en) Model of autoimmune disease and methods for identifying agents against autoimmune disease
EP1020529A3 (en) Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
AU1306899A (en) Mammalian pro-apoptotic bok genes and their uses
AU8999198A (en) Viral vector system capable of expressing an apoptosis-associated gene
AU5293198A (en) Promoter of the human endoglin gene and its use
WO1998046747A3 (en) Genes in the non-recombining region of the y chromosome
FR2799472B1 (en) PREPARATION OF RECOMBINANT ADENOVIRUSES AND ADENOVIRAL BANKS
AU2233297A (en) Promoter

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: C2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 6 AND 8, DESCRIPTION, REPLACED BY NEW PAGES 6 AND 8; AFTER RECTIFICATION OF OBVIOUS ERRORS ASAUTHORIZED BY THE INTERNATIONAL SEARCHING AUTHORITY

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase